Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Amgen Inc. et al v. Hospira, Inc. et al
Case Number:
1:20-cv-00201
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
March 21, 2022
Amgen Agrees To End Neulasta IP Suit Against Pfizer, Hospira
Biopharmaceutical company Amgen has agreed to drop its patent infringement suit against its rivals, Pfizer and Hospira, asking a Delaware federal judge Monday to end the two-year feud over claims of their post-chemotherapy treatment being nearly identical to Amgen's Neulasta.
-
February 12, 2020
Amgen Sues Pfizer, Hospira As Neulasta Patent Feud Widens
Pfizer Inc. and Hospira Inc. infringed an Amgen Inc. patent when seeking to get its biosimilar of Amgen's blockbuster anti-infection medicine Neulasta on the market before the patent expired, the biologic maker told a Delaware federal court.